Search

Author/Creator Janni, W

1. 273PD_PRFinal analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. (23rd October 2018)

Authors:
Reinisch, M; Seiler, S; Hauzenberger, T; Schmatloch, S; Strittmatter, H-J; Zahm, D-M; Thode, C; Jackisch, C; Strik, D; Moebus, V; Reimer, T; Sinn, B; Stickeler, E; Marme, F; Janni, W; Kamischke, A; Rudlowski, C; Nekljudova, V; von Minckwitz, G; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. EP385 A single-center retrospective analysis to evaluate the prognostic role of lymph node density in patients with lymph node positive cervical cancer. (1st November 2019)

Authors:
Polasik, A; Janni, W; Scholz, C; De Gregorio, N; Schochter, F; Friedl, TWP; Widschwendter, P
Journal:
International journal of gynecological cancer
Issue:
Volume 29(2019)Supplement 4
Page Start:
A259
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Issue 5 (1st September 2007)

Authors:
Schindlbeck, C; Hantschmann, P; Zerzer, M; Jahns, B; Rjosk, D; Janni, W; Rack, B; Sommer, H; Friese, K
Journal:
International journal of gynecological cancer
Issue:
Volume 17:Issue 5(2007)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. (11th June 2018)

Authors:
Ignatiadis, M; Litière, S; Rothe, F; Riethdorf, S; Proudhon, C; Fehm, T; Aalders, K; Forstbauer, H; Fasching, P A; Brain, E; Vuylsteke, P; Guardiola, E; Lorenz, R; Pantel, K; Tryfonidis, K; Janni, W; Piccart, M; Sotiriou, C; Rack, B; Pierga, J -Y
Journal:
Annals of oncology
Issue:
Volume 29:Number 8(2018)
Page Start:
1777
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (13th August 2019)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 30:Number 11(2019)
Page Start:
1842
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. (27th April 2018)

Authors:
Hortobagyi, G N; Stemmer, S M; Burris, H A; Yap, Y S; Sonke, G S; Paluch-Shimon, S; Campone, M; Petrakova, K; Blackwell, K L; Winer, E P; Janni, W; Verma, S; Conte, P; Arteaga, C L; Cameron, D A; Mondal, S; Su, F; Miller, M; Elmeliegy, M; Germa, C
Journal:
Annals of oncology
Issue:
Volume 29:Number 7(2018)
Page Start:
1541
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗